Trump Jr.'s BlinkRx Board Seat Aligns with Administration's Drug Pricing Push

After President Trump sent letters on July 31, 2025 urging 17 pharmaceutical CEOs to sell drugs directly to consumers, BlinkRx, a digital pharmacy company where Donald Trump Jr. sits on the board, launched a service called Operation Access Now promising to help drugmakers build direct-to-consumer programs within 21 days. Trump Jr.'s investment fund, 1789 Capital, had previously led a $140 million funding round for BlinkRx before he joined its board in early 2025.

The overlap drew Senate scrutiny because a policy directive from the president created an immediate business opportunity for a company tied to his son. A separate strand of the same story involves Commerce Secretary Howard Lutnick, whose adult children now run Cantor Fitzgerald after he transferred his ownership into family trusts; Cantor Fitzgerald has taken financial stakes in companies positioned to benefit from the administration's push to reshore pharmaceutical manufacturing.

No law prohibits family members of officials from holding business interests that benefit from administration policy, and BlinkRx's service was available to any drugmaker. Critics argue the appearance of insider advantage nonetheless undermines public confidence that the drug-pricing overhaul was designed solely around patient affordability rather than family financial interests.